Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo

Metabolism: Clinical and Experimental

Volumn 60, Issue 8, 2011, Pages 1090-1099

  Wang, Shaoyun ^a   Kamat, Amrita ^a,b   Pergola, Pablo ^a   Swamy, Anita ^a   Tio, Fermin ^a,b   Cusi, Kenneth ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID; GLUCOSE; INSULIN; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOLOGY; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID DIET; LIPOGENESIS; MITOCHONDRIAL GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; CARNITINE O-PALMITOYLTRANSFERASE; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION; GENES, MITOCHONDRIAL; INSULIN; LIVER; MITOCHONDRIA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79960555502     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.12.001     Document Type: Article

References (62)

1. Cusi K. Nonalcoholic fatty liver disease: an overlooked complication of type 2 diabetes Pract Diabetol 27 2008 18 24
2. Browning J.D., Szczepaniak L.S., and Dobbins R. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395 (Pubitemid 39657013)
3. Ali R., and Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) Ann Med 41 2009 265 278
4. Bugianesi E., Gastaldelli A., and Vanni E. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms Diabetologia 48 2005 634 642 (Pubitemid 40591217)
5. Gastaldelli A., Cusi K., and Pettiti M. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects Gastroenterology 133 2007 496 506 (Pubitemid 47187337)
6. Korenblat K.M., Fabbrini E., and Mohammed B.S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects Gastroenterology 134 2008 1369 1375 (Pubitemid 351615354)
7. Kotronen A., Juurinen L., and Tiikkainen M. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes Gastroenterology 135 2008 122 130 (Pubitemid 351899009)
8. Harrison S., and Day C. Benefits of lifestyle modification in NAFLD Gut 56 2007 1760 1769
9. Belfort R., Harrison S.A., and Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 2297 2307 (Pubitemid 44837778)
10. Ratziu V., Giral P., and GJacqueminet S. and The Lido Study Group. Rosiglitazone for NASH: one year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial Gastroenterology 135 2008 100 110 (Pubitemid 351916703)
11. Aithal G.P., Thomas J.A., and Kaye P.V. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology 135 2008 1176 1184
12. Sanyal A., Chalasani N., Kowdley K. for the NASH CRN Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
13. Bugianesi E., Marzocchi R., and Villanova N. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment Best Pract Res Clin Gastroenterol 18 2004 1105 1116 (Pubitemid 39517695)
14. Caldwell S., Argo C., and Al-Osaimi A. Therapy of NAFLD: insulin sensitizing agents J Clin Gastroenterol 40 2006 S61 S66
15. Caldwell S., Chang Y., and Nakamoto R. Mitochondria in nonalcoholic fatty liver disease Clin Liver Dis 8 2004 595 617 (Pubitemid 39141145)
16. Begriche K., Igoudjil A., Pessayre D., and Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it Mitochondrion 6 2006 1 28
17. Cusi K. Role of liver insulin resistance and lipotoxicity in NASH Clin Liver Dis 13 2009 545 563
18. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury J Clin Invest 114 2004 147 152 (Pubitemid 39071617)
19. Luo J., Quan J., and Tsai J. Nongenetic mouse models of non-insulin-dependent diabetes mellitus Metabolism 47 1998 663 668 (Pubitemid 28265168)
20. Danda R., Habiba N., and Rincon-Choles H. Kidney involvement in a nongenetic rat model of type 2 diabetes Kidney Int 68 2005 2562 2571 (Pubitemid 43251001)
21. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology Diabetes & Obesity 16 2009 141 149
22. Cannino G., Di Liegro C.M., and Rinaldi A.M. Nuclear-mitochondrial interaction Mitochondrion 7 2007 359 366 (Pubitemid 350082356)
23. Liang H., and Ward W. PGC-1alpha: a key regulator of energy metabolism Adv Physiol Educ 30 2006 145 151 (Pubitemid 44749372)
24. Kallwitz E., McLachlan A., and Cotler S. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease World J Gastroenterol 14 2008 22 28 (Pubitemid 351314322)
25. Lee S., Pineau T., and Drago J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol Cell Biol 15 1995 3012 3022
26. Patsouris D., Reddy J.K., and Muller M. Peroxisome proliferator-activated receptor-α mediates the effects of high-fat diet on hepatic gene expression Endocrinology 147 2006 1508 1516 (Pubitemid 43244386)
27. Herzig S., Fanxin L., and Jhala U. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1 Nature 413 2001 179 183 (Pubitemid 32867880)
28. Yoon J., Puigserver P., and Chen G. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 Nature 413 2001 131 138 (Pubitemid 32867868)
29. Li X., Monks B., and Ge Q. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator Nature 447 2007 1012 1016 (Pubitemid 46975750)
30. Puigserver P., Rhee J., and Donovan J. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction Nature 423 2003 550 555 (Pubitemid 36648580)
31. Semple R., Sleigh A., and Murgatroyd P. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis J Clin Invest 119 2009 315 322
32. Wu Z., Puigserver P., and Andersson U. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 Cell 98 1999 115 124 (Pubitemid 29331201)
33. Estall J.L., Ruas J.L., and Choi C.S. PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis Proc Natl Acad Sci USA 106 2009 22510 22515
34. Crunkhorn S., Dearie F., Mantzoros C., Gami H., da Silva W.S., and Espinoza D. Peroxisome proliferator activator receptor coactivator-1 expression is reduced in obesity J Biol Chem 282 2007 15439 15450
35. Richardson D.K., Kashyap S., Bajaj M., Cusi K., Mandarino S.J., and Finlayson J. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle J Biol Chem 280 2005 10290 10297 (Pubitemid 40395885)
36. Ruschke K., Fishbein L., Dietrich A., Kloting N., Tonjes A., and Oberbach A. Gene expression of PPARγ and PGC-1α in human omental and subcutaneous adipose tissues is related to insulin resistance markers and mediates beneficial effects of physical training Eur J Endocrinol 162 2010 515 523
37. De Filippis E., Alvarez G., Berria R., Cusi K., Everman S., and Meyer C. Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise Am J Physiol Endocrinol Metab 294 2008 E607 614
38. Cusi K. Role of adipose tissue insulin resistance and lipotoxicity in the development of type 2 diabetes mellitus Curr Diab Rep 10 2010 306 315
39. Jacobs M., van Greevenbroek M.M., van der Kallen C.J., Ferreira I., Feskens E.J., and Jansen E.H. The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study) Metabolism 2010 10.1016/j.metabol.2010.09.006 in press
40. Gastaldelli A., Harrison S., Belfort R., Hardies J., Balas B., and Schenker S. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis Hepatology 50 2009 1087 1093
41. Lee Y., Yu X., and Gonzalez F. PPAR-α is necessary for the lipogenic action of hyperleptinemia on white adipose and liver tissue Proc Nat Acad Sciences 99 2002 11848 11853 (Pubitemid 34994487)
42. Javor E., Ghany M., and Cochran E.O. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy Hepatology 41 2005 753 760 (Pubitemid 40462937)
43. Wang J., Obici S., and Morgan K. Overfeeding rapidly induces leptin and insulin resistance Diabetes 50 2001 2786 2791 (Pubitemid 33733130)
44. Le D., Marks D., and Lyle E. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients Surgical Endosc 21 2007 1593 1599 (Pubitemid 47353488)
45. Tsochatzis E., Papatheodoridis G., and Archimandritis A. The evolving role of leptin and adiponectin in chronic liver disease Am J Gastroenterol 101 2006 2629 2640. (Pubitemid 44665263)
46. Bertolani C., and Marra F. The role of adipokines in liver fibrosis Pathophysiology 15 2008 91 101
47. Larter C., Yeh M., and Williams J. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes J Hepatology 49 2008 407 416
48. Roglans N., Vila L., and Farre M. Impairment of hepatic Stat-3 activation and reduction of PPARα activity in fructose-fed rats Hepatology 45 2007 778 788 (Pubitemid 46450629)
49. Bullen J.W., Bluher S., Kelesidis T., and Mantzoros C.S. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice Am J Physiol Endocrinol Metab 292 2007 1079 1086
50. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., and Takekawa S. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity J Biol Chem 279 2004 30817 30822 (Pubitemid 38938015)
51. Belfort R., Berria R., Cornell J., and Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome J Clin Endocrinol Metab 95 2010 829 836
52. Lihn A.S., Ostergard T., Nyholm B., Pedersen S.B., Richelsen B., and Schmitz O. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients Am J Physiol Endocrinol Metab 284 2003 E443 448
53. Civitarese A., Jenkinson C., Richardson D., Bajaj M., Cusi K., and Kashyap S. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes Diabetologia 47 2004 816 820 (Pubitemid 38756993)
54. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., and Pons-Romero F. Adiponectin and its receptors in non-alcoholic steatohepatitis Gut 54 2005 117 121 (Pubitemid 40007229)
55. Baranova A., Gowder S.J., Schlauch K., Elariny H., Collantes R., and Afendy A. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance Obes Surg 16 2006 1118 1125 (Pubitemid 44433145)
56. Gastaldelli A., Harrison S., Belfort-Aguiar A., Hardies J., Balas B., Schenker S., and Cusi K. Pioglitazone in the treatment of NASH: role of adiponectin Aliment Pharmacol Ther 32 2010 769 775
57. Martocchia A., Risicato M., Mattioli C., Antonelli M., Ruco L., and Falaschi P. Association of diffuse liver glycogenosis and mild focal macrovesicular steatosis in a patient with poorly controlled type 1 diabetes Intern Emerg Med 3 2008 273 274
58. Satapati S., He T., and Inagaki T. Partial resistance to peroxisome proliferator-activated receptor-α agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism Diabetes 57 2008 2012 2021
59. Chakravarthy M., Pan Z., and Zhu Y. "New" hepatic fat activates PPAR-α to maintain glucose, lipid, and cholesterol homeostasis Cell Metab 1 2005 309 322 (Pubitemid 43977168)
60. Olefsky J. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists J Clin Invest 106 2000 467 472 (Pubitemid 30666379)
61. Fabbrini E., Mohammed B.S., Korenblat K.M., Magkos F., McCrea J., and Patterson B.W. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease J Clin Endocrinol Metab 95 2010 2727 2735
62. García-Ruiz I., Rodríguez-Juan C., Díaz- Sanjuán T., Martínez M., Muñoz-Yagüe T., and Solís-Herruzo J. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice Hepatology 46 2007 414 423 (Pubitemid 47344776)